HK Stock Market Move | GenScript Bio (01548) rose over 13% in the afternoon, with second quarter CARVYKTI sales reaching $657 million, a year-on-year increase of nearly 50%.

Genscript Bio (01548) rose more than 13% in the afternoon, up 11.66% to HK$16.37 as of the time of publication, with a turnover of HK$754 million. On the news front, Genscript Bio recently announced that sales of its legend bio-CARVYKTI reached $657 million in the second quarter, an increase of 49.4% year-on-year and 10% quarter-on-quarter. Sales in the first half of the year reached $1.254 billion, an increase of 55.1% year-on-year. The annual sales are expected to exceed $2.5 billion. Public information shows that as of now, CARVYKTI has already treated over 10,000 patients. It is worth noting that President Trump announced that he will impose a 100% tariff on generic drugs two years later. Analysts point out that the policy may have limited direct impact on innovative drugs, but it may force companies to expand their production capacity in the US ahead of schedule. It is reported that Johnson & Johnson and Genscript Bio have already established commercial production bases in the US, New Jersey, and Ghent, Belgium, in addition to commissioning CMO and internal new production line planning. In the coming years, the annual production capacity of CARVYKTI is expected to achieve a multiple expansion on the existing basis.